At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Trading 08-05 11:17:30 EDT
194.68
+1.22
+0.63%
High198.30Low192.56Vol508.97K
Open194.10D1 Closing193.46Amplitude2.96%
Mkt Cap41.39BTradable Cap39.02BTotal Shares212.59M
T/O99.67MT/O Rate0.25%Tradable Shares200.43M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally
Market Focus  ·  00:35
Movement Alert｜Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally
Revolution Medicines Inc Expected to Post a Loss of $1.98 a Share - Earnings Preview
Reuters  ·  08-04 07:55
Revolution Medicines Inc Expected to Post a Loss of $1.98 a Share - Earnings Preview
Jefferies Cuts Ipsen to 'underperform' on Somatuline Competition Risk
Reuters  ·  08-03 15:00
Jefferies Cuts Ipsen to 'underperform' on Somatuline Competition Risk
FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)
Simply Wall St.  ·  07-31
FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)
Movement Alert｜Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price
Market Focus  ·  07-31
Movement Alert｜Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price
Revolution Medicines to Report Q2 Financial Results After Market Close, Hosts Webcast Update
Reuters  ·  07-30
Revolution Medicines to Report Q2 Financial Results After Market Close, Hosts Webcast Update
Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid
Simply Wall St.  ·  07-24
Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid
Revolution Medicines is Maintained at Outperform by Wedbush
Dow Jones  ·  07-23
Revolution Medicines is Maintained at Outperform by Wedbush
Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA
Market Focus  ·  07-23
Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA
Revolution Medicines Inc : Wedbush Raises Target Price to $192.1 from $181
THOMSON REUTERS  ·  07-23
Revolution Medicines Inc : Wedbush Raises Target Price to $192.1 from $181
Wedbush Raises Price Target on Revolution Medicines to $192.10 From $181, Keeps Outperform Rating
MT Newswires Live  ·  07-23
Wedbush Raises Price Target on Revolution Medicines to $192.10 From $181, Keeps Outperform Rating
Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target
TIPRANKS  ·  07-23
Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target
Revolution Medicines receives FDA review acceptance for daraxonrasib
TIPRANKS  ·  07-23
Revolution Medicines receives FDA review acceptance for daraxonrasib
Revolution Medicines Says FDA Accepts Daraxonrasib NDA for Previously Treated Metastatic Pancreatic Cancer
Reuters  ·  07-23
Revolution Medicines Says FDA Accepts Daraxonrasib NDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
THOMSON REUTERS  ·  07-23
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines is Maintained at Buy by Needham
Dow Jones  ·  07-20
Revolution Medicines is Maintained at Buy by Needham
Movement Alert｜Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36
Market Focus  ·  07-17
Movement Alert｜Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36
Revolution Medicines Inc : JP Morgan Raises Target Price to $205 from $200
THOMSON REUTERS  ·  07-16
Revolution Medicines Inc : JP Morgan Raises Target Price to $205 from $200
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)
TIPRANKS  ·  07-11
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)
Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)
TIPRANKS  ·  07-10
Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--